CHCWM – Cancer & Hematology Centers of West Michigan

Merck MK-7339-003 (LYNK-003)

A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003)

Principal Investigator: Dr. Sreenivasa Chandana

For more information on this trial, read its profile on clinicaltrials.gov here.